Skip to main content
Fig. 5 | Journal of Experimental & Clinical Cancer Research

Fig. 5

From: Splicing targeting drugs highlight intron retention as an actionable vulnerability in advanced prostate cancer

Fig. 5

Pervasive intron retention is induced by splicing inhibitors in 22Rv1 cells. A For each indicated drug, the left pie chart illustrates the percentages of exonic (light blue) and intronic (purple) regulated events and the right pie chart highlights the percentages of up- (red) and downregulated (green) events within the subset of intronic events. B Box plots showing the expression levels (log2 FPKM) of regulated (light blue bar) and unaffected genes (reference, grey bar) by intron-retention in 22Rv1 cells treated with indicated drugs. C Curve graphs showing distribution of the upregulated introns (red line) by indicated drugs within the transcription unit of their hosting genes (5′ → 3’ direction). D-G Boxplots showing comparison between up-regulated introns (red boxes) by indicated splicing inhibitors (Ind = indisulam, Pb = Pladienolide B, THZ = THZ531) and other not-regulated intron-retention events (ref. intron, blue boxes) and properly spliced-introns (ref. constitutive, grey box) for indicated features. In B and D-G Whiskers indicate 1.5 interquartile range and highlighted circles the mean values (Welch’s t test). Number of analysed exons within each groups is indicated in Additional File 2: Fig S7.

Back to article page